<!DOCTYPE html>
<html lang="en" xml:lang="en" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta charset="utf-8"/>
<meta content="SAS 9.4" name="generator"/>
<title>SAS Output</title>
<style>
/*<![CDATA[*/
.body.c > table, .body.c > pre, .body.c div > table,
.body.c div > pre, .body.c > table, .body.c > pre,
.body.j > table, .body.j > pre, .body.j div > table,
.body.j div > pre, .body.j > table, .body.j > pre,
.body.c p.note, .body.c p.warning, .body.c p.error, .body.c p.fatal,
.body.j p.note, .body.j p.warning, .body.j p.error, .body.j p.fatal,
.body.c > table.layoutcontainer, .body.j > table.layoutcontainer { margin-left: auto; margin-right: auto }
.layoutregion.l table, .layoutregion.l pre, .layoutregion.l p.note,
.layoutregion.l p.warning, .layoutregion.l p.error, .layoutregion.l p.fatal { margin-left: 0 }
.layoutregion.c table, .layoutregion.c pre, .layoutregion.c p.note,
.layoutregion.c p.warning, .layoutregion.c p.error, .layoutregion.c p.fatal { margin-left: auto; margin-right: auto }
.layoutregion.r table, .layoutregion.r pre, .layoutregion.r p.note,
.layoutregion.r table, .layoutregion.r pre, .layoutregion.r p.note,
.layoutregion.r p.warning, .layoutregion.r p.error, .layoutregion.r p.fatal { margin-right: 0 }
article, aside, details, figcaption, figure, footer, header, hgroup, nav, section { display: block }
html{ font-size: 100% }
.body { margin: 1em; font-size: 13px; line-height: 1.231 }
sup { position: relative; vertical-align: baseline; bottom: 0.25em; font-size: 0.8em }
sub { position: relative; vertical-align: baseline; top: 0.25em; font-size: 0.8em }
ul, ol { margin: 1em 0; padding: 0 0 0 40px }
dd { margin: 0 0 0 40px }
nav ul, nav ol { list-style: none; list-style-image: none; margin: 0; padding: 0 }
img { border: 0; vertical-align: middle }
svg:not(:root) { overflow: hidden }
figure { margin: 0 }
table { border-collapse: collapse; border-spacing: 0 }
.layoutcontainer { border-collapse: separate; border-spacing: 0 }
p { margin-top: 0; text-align: left }
h1.heading1 { text-align: left }
h2.heading2 { text-align: left }
h3.heading3 { text-align: left }
h4.heading4 { text-align: left }
h5.heading5 { text-align: left }
h6.heading6 { text-align: left }
span { text-align: left }
table { margin-bottom: 1em }
td, th { text-align: left; padding: 3px 6px; vertical-align: top }
td[class$="fixed"], th[class$="fixed"] { white-space: pre }
section, article { padding-top: 1px; padding-bottom: 8px }
hr.pagebreak { height: 0px; border: 0; border-bottom: 1px solid #c0c0c0; margin: 1em 0 }
.stacked-value { text-align: left; display: block }
.stacked-cell > .stacked-value, td.data > td.data, th.data > td.data, th.data > th.data, td.data > th.data, th.header > th.header { border: 0 }
.stacked-cell > div.data { border-width: 0 }
.systitleandfootercontainer { white-space: nowrap; margin-bottom: 1em }
.systitleandfootercontainer > p { margin: 0 }
.systitleandfootercontainer > p > span { display: inline-block; width: 100%; white-space: normal }
.batch { display: table }
.toc { display: none }
.proc_note_group, .proc_title_group { margin-bottom: 1em }
p.proctitle { margin: 0 }
p.note, p.warning, p.error, p.fatal { display: table }
.notebanner, .warnbanner, .errorbanner, .fatalbanner,
.notecontent, .warncontent, .errorcontent, .fatalcontent { display: table-cell; padding: 0.5em }
.notebanner, .warnbanner, .errorbanner, .fatalbanner { padding-right: 0 }
.body > div > ol li { text-align: left }
.beforecaption > h4 { margin-top: 0; margin-bottom: 0 }
.c { text-align: center }
.r { text-align: right }
.l { text-align: left }
.j { text-align: justify }
.d { text-align: right }
.b { vertical-align: bottom }
.m { vertical-align: middle }
.t { vertical-align: top }
.accessiblecaption {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.aftercaption {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.batch > col, .batch > colgroup > col, .batch > colgroup, .batch > tr, .batch > * > tr, .batch > thead, .batch > tbody, .batch > tfoot { border: none; }
.batch {
    background-color: #ffffff;
    border-style: solid;
    border-collapse: separate;
    border-spacing: 1px;
    color: #003399;
    font-family: 'SAS Monospace', 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    padding: 7px;
    }
.beforecaption {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.body {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    margin-left: 8px;
    margin-right: 8px;
}
.bodydate {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    text-align: right;
    vertical-align: top;
    width: 100%;
}
.bycontentfolder {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: none;
    margin-left: 6pt;
}
.byline {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.bylinecontainer > col, .bylinecontainer > colgroup > col, .bylinecontainer > colgroup, .bylinecontainer > tr, .bylinecontainer > * > tr, .bylinecontainer > thead, .bylinecontainer > tbody, .bylinecontainer > tfoot { border: none; }
.bylinecontainer {
    background-color: #ffffff;
    border: none;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.caption {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.cell, .container {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.contentfolder, .contentitem {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: none;
    margin-left: 6pt;
}
.contentproclabel, .contentprocname {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
}
.contents {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
    margin-left: 8px;
    margin-right: 8px;
}
.contentsdate {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.contenttitle {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.continued {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
    width: 100%;
}
.data {
    background-color: #ffffff;
    color: #000000;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.dataemphasis {
    background-color: #ffffff;
    color: #000000;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.dataemphasisfixed {
    background-color: #ffffff;
    color: #000000;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.dataempty {
    background-color: #ffffff;
    color: #000000;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.datafixed {
    background-color: #ffffff;
    color: #000000;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.datastrong {
    background-color: #ffffff;
    color: #000000;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.datastrongfixed {
    background-color: #ffffff;
    color: #000000;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.date {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.document, .errorbanner, .errorcontent {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.errorcontentfixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.extendedpage {
    background-color: #ffffff;
    border-style: solid;
    border-width: 1pt;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
    text-align: center;
}
.fatalbanner, .fatalcontent {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.fatalcontentfixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.folderaction {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.footer {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.footeremphasis {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.footeremphasisfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.footerempty {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.footerfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.footerstrong {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.footerstrongfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.frame {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.graph > col, .graph > colgroup > col, .graph > colgroup, .graph > tr, .graph > * > tr, .graph > thead, .graph > tbody, .graph > tfoot { border: none; }
.graph {
    background-color: #ffffff;
    border-style: solid;
    border-collapse: separate;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    }
.header {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.headeremphasis {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.headeremphasisfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.headerempty {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.headerfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.headersandfooters, .headerstrong {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.headerstrongfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.index, .indexaction {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.indexitem {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: none;
    margin-left: 6pt;
}
.indexprocname {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
}
.indextitle, .linecontent, .list, .list10, .list2, .list3, .list4, .list5, .list6, .list7, .list8, .list9, .listitem, .listitem10, .listitem2, .listitem3, .listitem4, .listitem5, .listitem6, .listitem7, .listitem8, .listitem9, .note, .notebanner, .notecontent {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.notecontentfixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.output > col, .output > colgroup > col, .output > colgroup, .output > tr, .output > * > tr, .output > thead, .output > tbody, .output > tfoot { border: none; }
.output {
    background-color: #cccccc;
    border-style: solid;
    border-collapse: separate;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    }
.pageno {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
    text-align: right;
    vertical-align: top;
}
.pages {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
    margin-left: 8px;
    margin-right: 8px;
}
.pagesdate {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.pagesitem {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: none;
    margin-left: 6pt;
}
.pagesproclabel, .pagesprocname {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
}
.pagestitle, .paragraph {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.parskip {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.prepage, .proctitle {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.proctitlefixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowfooter {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowfooteremphasis {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.rowfooteremphasisfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.rowfooterempty {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowfooterfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.rowfooterstrong {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowfooterstrongfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowheader {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowheaderemphasis {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.rowheaderemphasisfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.rowheaderempty {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowheaderfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.rowheaderstrong {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowheaderstrongfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.systemfooter, .systemfooter10, .systemfooter2, .systemfooter3, .systemfooter4, .systemfooter5, .systemfooter6, .systemfooter7, .systemfooter8, .systemfooter9 {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: bold;
}
.systemtitle, .systemtitle10, .systemtitle2, .systemtitle3, .systemtitle4, .systemtitle5, .systemtitle6, .systemtitle7, .systemtitle8, .systemtitle9 {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: medium;
    font-style: normal;
    font-weight: bold;
}
.systitleandfootercontainer > col, .systitleandfootercontainer > colgroup > col, .systitleandfootercontainer > colgroup, .systitleandfootercontainer > tr, .systitleandfootercontainer > * > tr, .systitleandfootercontainer > thead, .systitleandfootercontainer > tbody, .systitleandfootercontainer > tfoot { border: none; }
.systitleandfootercontainer {
    background-color: #ffffff;
    border: none;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.table > col, .table > colgroup > col, .table > colgroup, .table > tr, .table > * > tr, .table > thead, .table > tbody, .table > tfoot { border: none; }
.table {
    background-color: #cccccc;
    border-style: solid;
    border-collapse: separate;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    }
.titleandnotecontainer > col, .titleandnotecontainer > colgroup > col, .titleandnotecontainer > colgroup, .titleandnotecontainer > tr, .titleandnotecontainer > * > tr, .titleandnotecontainer > thead, .titleandnotecontainer > tbody, .titleandnotecontainer > tfoot { border: none; }
.titleandnotecontainer {
    background-color: #ffffff;
    border: none;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.titlesandfooters, .usertext, .warnbanner, .warncontent {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.warncontentfixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
/*]]>*/
</style>
</head>
<body class="c body">
<div style="padding-bottom: 8px; padding-top: 1px">
<div id="IDX" class="systitleandfootercontainer" style="border-spacing: 1px">
<p><span class="c systemtitle">Lipids data set 3</span> </p>
</div>
<div style="padding-bottom: 8px; padding-top: 1px">
<table class="table" style="border-spacing: 1px" aria-label="Data Set REF.LIPIDS_SORTED_3">
<caption aria-label="Data Set REF.LIPIDS_SORTED_3"></caption>
<colgroup><col/><col/><col/><col/></colgroup>
<thead>
<tr>
<th class="r header" scope="col">sub_ref_no</th>
<th class="header" scope="col">Strengths</th>
<th class="header" scope="col">Weaknesses</th>
<th class="header" scope="col">Future_Research</th>
</tr>
</thead>
<tbody>
<tr>
<td class="r data">1</td>
<td class="data"> &#160;</td>
<td class="data"> &#160;</td>
<td class="data">However, the interrelation between HDL lipidome, proteome and particle functionality is a missing part of the puzzle, which remains as yet unsolved.  XXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">2</td>
<td class="data"> &#160;</td>
<td class="data">However, there are some limitations in the current studies. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX First, the physiological roles of miR-320 under normal conditions in various organs are missing. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Second, the effect of miR-320 on glucose and lipid metabolism is not investigated by the mutual regulation of multiple organs. Furthermore, certain organs are composed of a variety of cell types, and different cell types may interact with each other by exosomes and other vesicles. Considering that the glucose and lipid metabolism disorder-associated diseases are systemic diseases, we should also pay attention to the interaction of miR-320 among certain organs and cell types. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Third, studies have reported the roles of miR-320 in various disease conditions using animal models, for example, I/R injury, but the expression patterns of miR-320 in related patients were less investigated, which limited the clinical prospect. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Finally, the mechanisms and functions of miR-320 were mainly investigated using expression vectors rather than genetically modified animal models. Although studies using miR-320 transgenic mice have been reported [150], up to now, the studies using miR-320 genetic knockout animal models have not been reported, which might be partially due to side effects on POLR3D. As reported previously, miR-320 is encoded directly upstream of the cell cycle gene POLR3D, which is a conserved subunit specific to RNA polymerase III and affects the overall function of the cell [19, 20]. It is worth noting that these models may be achieved by CRISPR-Cas9 or single base site-directed mutations, without affecting the function of POLR3D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data"> &#160;</td>
</tr>
<tr>
<td class="r data">3</td>
<td class="data">A strength of the current study is that it included a large number of participants with a varied age range and with a follow-up period of 7.3 years. Furthermore, in sensitivity analysis applying the proportion of HDL subspecies, the inverse association of H4P and the positive association of H2P with incident T2D remained, significant, in fully adjusted analyses. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">A limitation of our study is that the majority of the participants were of White ethnic background, limiting extrapolation of our findings to other ethnicities. In this regard, it may be of importance that the inverse association of HDL-C and HDL-P with cardiovascular disease is absent in Black people (67). XXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">However, paraoxonase-1 activity did not predict T2D development, making the role of this antioxidative enzyme in T2D development uncertain (61). XXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">4</td>
<td class="data">One key strength of the study is that the genetic associations were derived on mainly fasting samples, which facilitates the interpretation of the results. Fasting measurements represent hepatic-derived lipid traits whereas non-fasting samples also partly reflect gut-derived contributions from chylomicron particles and their remnants. This means that our analysis is well placed to answer causal questions about endogenous lipid pathways, but is less able to answer questions about lipoproteins from dietary sources. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">Previous studies have suggested that the ApoB / ApoA1 ratio may be a relevant risk factor for CAD. (26) However, working on summary-level data we were not able to investigate any other relevant risk factors than those provided by the original data, such as the ratio ApoB / ApoA1 or the ratio of LDL / HDL particles. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A further limitation is that there is overlap between individuals in the outcome datasets for the main and sensitivity analyses. For this reason, we refer to them as sensitivity analyses rather than replication analyses, as they assess the robustness of the variable selection algorithm to variations in the outcome dataset, rather than providing an independent replication of the findings. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data"> &#160;</td>
</tr>
<tr>
<td class="r data">5</td>
<td class="data"> &#160;</td>
<td class="data"> &#160;</td>
<td class="data">The future research elucidating these important queries holds great promise in not only understanding how ceramides modulate nutrient sensing that underlies metabolic disease processes but also potentially identifying new therapeutic targets to combat metabolic diseases epidemic.</td>
</tr>
<tr>
<td class="r data">6</td>
<td class="data">The strengths of the current study include the use of an efficiently designed case-cohort study from a wellcharacterised clinical trial to yield a powerful study for a range of outcomes, which were independently adjudicated according to pre-specified criteria. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This study included multiple plasma fatty acids and the ability to adjust for multiple covariates including lipids and lipid-lowering drugs, such as statins. We also considered the percentage that individual fatty acids contributed to total fatty acids, as well as the absolute levels of fatty acid, and both measures are important for interpreting fatty acid values since an increased intake of a specific fatty acid could alter the relative percentage of other fatty acids while their absolute levels are unlikely to be altered. XXX  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">The present study, however, has several limitations. First, as the study cohort was derived from a randomised trial of individuals with type 2 diabetes, our results may have limited generalisability to broader populations. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Second, as fatty acids were measured in pragmatically collected plasma samples in a randomised trial, we cannot rule out the potential for differential pre-analytical sample handling or sample degradation during storage, which may have biased our results [49]. Further, as plasma samples were collected from non-fasted participants, the levels of fatty acids might have been affected by the consumption of a recent meal [50], although, in clinical practice, fasting is rarely required among individuals with type 2 diabetes. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Third, fatty acids were only measured in plasma samples collected at study baseline; thus, we were unable to consider how the change in fatty acid values during the study follow-up might have influenced the exposure–outcome association. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Finally, our study considered only two individual fatty acids (DHA and LA), since the resolution of the employed high throughput NMR platform was limited in terms of individual fatty acid types, and only allowed robust quantification of DHA within n-3, and LA within n-6. The specific set of measures was determined by their overall concentration in plasma and also on spectroscopic aspects, such as overlapping signals, which makes it challenging to quantify from native plasma where no lipid extraction is used [14]. LA and DHA were reported since they generate distinct peaks in the spectral data produced by the measurement, and we were able quantify them separately as part of our high-throughput service. However, fatty acid concentrations quantified by the NMR metabolomics platform were highly consistent with the concentrations compared with GC, the latter being challenging with large samples [46]. Further, NMR, is a novel technology with the potential of offering a cost-effective platform for multiple biomarker testing and has great potential in regard to fatty acid measurement. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">Further investigation of the benefits of n-3 fatty acid supplementation will, therefore, be required among people with type 2 diabetes and high CVD risks. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">7</td>
<td class="data">The major strengths of this study are the large number of individuals with T2D from 5 independent cohorts as well as adjustment for an extensive set of relevant clinical covariates and multiple testing, which diminished the risk of false-positive results. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Moreover, the use of the NMR platform provided standardized measures of metabolites, allowing exploration of measures beyond routinely measured biomarkers. This method was faster, cheaper, and thereby more accessible than the more extensive MS-based metabolomics methods and could potentially be easier to adapt to a clinical setting, although it did not provide as in-depth a characterization as, for example, MS. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The use of medications agents may affect the metabolome substantially. In a recently published paper, also from the Biobanking and Biomolecular Resources Research Infrastructure consortium, significant associations between cardiometabolic agents and several of the measured metabolites were demonstrated (44). In the present study, results were adjusted for several medications commonly used in diabetes. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">We further recognize some limitations of the study. Metabolites were measured at one timepoint and therefore did not provide information regarding within-subject variation 
in metabolite levels. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In some of the original studies, information regarding albuminuria measurements and history of micro- or macroalbuminuria was very limited. Further, we were limited by a low number of cases in the CODAM study, no diabetes duration in the RS study, and only having follow-up measurements from 2 cohorts. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Information regarding diet, which may affect the measured metabolites, was not available in all cohorts and not uniformly captured. Therefore, we could not  control for diet in this study. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Information regarding other renal markers, such as vitamin D, parathyroid hormone, and calcium, was also not available. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Since the samples originate from different studies, the storage time before metabolite measurements differed. Although all samples were stored at −80°C as recommended (45), we did find consistent results across studies, regardless of the year of sampling. This finding was also demonstrated by low heterogeneity between studies, suggesting no such influence. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">Further longitudinal studies are needed to clarify whether alterations in metabolite levels precede or are consequences of renal impairment and whether a biomarker panel of both amino acid and lipid measures could potentially lead to improved prediction in the development of DKD. XXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">8</td>
<td class="data"> &#160;</td>
<td class="data"> &#160;</td>
<td class="data">While these findings are of interest, given the extensive literature on altered choline metabolism and liver disease (18–25), they do not prove cause and effect and call for further mechanistic studies.   XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX   All of these features are geometrically opposite to those observed in choline-deficient models in mice and humans and suggest that HSD17B13 might be an attractive pharmaceutical target in liver disease. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">9</td>
<td class="data">The advantage is that the bioinformatic approach incorporates molecular pathway information associated with disease progression as well as biomarkers and pathway information associated with drug response, thereby decreasing the probability of false positive findings. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">A limitation is that the bioinformatic approach only includes molecular features and molecular pathways which have previously been annotated and does not include novel mechanisms. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The limitations of this study include the small sample size, which hampers the statistical power of this study as well as the generalizability to the broader type 2 diabetes population because the studied population was a predominantly male Caucasian population. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Although we compared the effect of dapagliflozin with placebo in an additional analysis, we only considered metabolites which statistically significantly changed from baseline during dapagliflozin treatment for further integration analysis because the metabolomics profile could only be determined in six patients in the placebo group. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Secondly, the short follow-up precluded assessment of the effect of dapagliflozin on eGFR decline. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Thirdly, the EFFECT II trial included patients with preserved kidney function, whereas tissue renal transcriptomics was performed in patients with preserved or impaired renal function participating in the ERCB study. It is possible that the effects of dapagliflozin on the metabolites are different in patients with different clinical characteristics, demographics and degrees of renal impairment. Hence, validation of our findings in larger studies with a longer duration as well as in patients with type 2 diabetes and chronic kidney disease, such as the DAPA-CKD trial, is required (36). Unfortunately, urine was not available, which could reveal a more renal specific signal. Nevertheless, our finding that metabolites related to mitochondrial function changed was in keeping with another study using urinary metabolites (25). XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">The exact mechanism of how SGLT2 inhibition improves endothelial function is not fully understood but may involve improved glycaemic and metabolic control, osmotic diuresis, and changes in sodium homeostasis as a result of increased natriuresis. XXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">10</td>
<td class="data"> &#160;</td>
<td class="data"> &#160;</td>
<td class="data">One necessary future development is post-selection inference (31, 32) in the high-dimensional multivariable MR framework. MR-BMA does not provide unbiased causal effect estimates. Re-fitting an unbiased multivariable MR model after risk factor selection would ignore the uncertainty of the selection and consequently not provide valid inferences. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">11</td>
<td class="data"> &#160;</td>
<td class="data">A major limitation of this MR study is that SNPs in the FADS1/2 gene cluster were associated with most fatty acids and only three or fewer SNPs were available as instrumental variables for individual fatty acids, except for POA. This limited the possibility for disentangling the association of individual fatty acids with type 2 diabetes, and performing sensitivity analyses to explore pleiotropy.</td>
<td class="data">Replication of our finding for POA in an independent MR study would provide strong evidence for a causal effect. Further research is needed to unravel the role of individual fatty acids in the prevention of type 2 diabetes. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">12</td>
<td class="data">The main strengths of our study include the case-cohort design nested within the PREDIMED trial, which enables the extension of the identified lipid patterns to all PREDIMED participants. Additionally, the analyses considering the complete lipidome allowed us to observe the effect of each lipid metabolite and each lipid group in the context of co-existing and interacting with the other plasma lipids. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">We acknowledge that despite our extensive adjustments, residual confounding cannot be ruled out. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Also, our results may not be generalizable to other populations because all study participants lived in a Mediterranean country and were at high cardiovascular risk. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Additionally, many of the participants who developed diabetes during the trial were people at high risk at baseline. At baseline, case subjects with T2D presented high mean levels of fasting glucose (117 +/- 18 mg/dL), which could be because many had prediabetes at baseline. Thus, the baseline lipid biomarkers could reflect an established prediabetic profile rather than a non-diabetic risk profile. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In this context, a recent study reported that plasma lipid profiles were similar in subjects with both prediabetes and diabetes (6), which indicates that our identified lipid patterns may be discriminating progressors versus non-progressors rather than healthy subjects versus subjects with T2D. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data"> &#160;</td>
</tr>
<tr>
<td class="r data">13</td>
<td class="data"> &#160;</td>
<td class="data"> &#160;</td>
<td class="data">However, the findings reported herein suggest that more extensive studies of the effects of these drugs on development during pregnancy should be undertaken to understand their potential risk. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Future studies with in vivo models seem to be called for because regulating DHCR24 activity may have some therapeutic benefits. In this regard, targeting Des levels as a therapy for neurodegeneration has been proposed, and masitinib is being repurposed as an adjuvant therapy for amyotrophic lateral sclerosis (47) and Alzheimer’s disease (AD) (48–50). Evidence suggests that masitinib is beneficial to patients with mild to moderate AD by normalizing neuronal signaling to support dendritic health (48). Yet, there are many findings that demonstrate that AD patients have perturbed sterol profiles (51) characterized by low Des levels in neuronal tissues (52, 53).</td>
</tr>
<tr>
<td class="r data">14</td>
<td class="data"> &#160;</td>
<td class="data"> &#160;</td>
<td class="data">Thus, whether certain dietary factors interact with the potential BCAA-biosynthetic component of the gut microbiome pattern, thereby affecting BCAA levels, deserves further investigation. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Despite the accumulating evidence that BCAAs are related to T2D pathogenesis, whether increased BCAA levels are a cause or consequence of T2D has not been elucidated. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX LysoPC is a signaling molecule involved in atherogenic and inflammatory processes (49), of which the major function needs to be clearly elucidated. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Given that food intake and relevant nutrients possibly interact with the environment and the gut microbiome, and that these interactions would be reflected in the blood metabolites, the links among dietary intake, gut microbiota and metabolic biomarkers and their associations with T2D must be further investigated. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Because the response to the specific stimulus (e.g. chemicals, nutrients, etc.) can be distinct depending on gender and ethnic group (62), separate analysis in a certain population is required to apply the identified metabolites for planning the preventive strategy as well as for pharmacological targeting to treat T2D.</td>
</tr>
<tr>
<td class="r data">15</td>
<td class="data"> &#160;</td>
<td class="data"> &#160;</td>
<td class="data">The medical and research communities need to prepare to give meaningful and helpful recommendations to concerned patients, including the woman described in the opening paragraph. Much more work is needed, and quickly, on this exciting class of bioactive lipids.  XXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">16</td>
<td class="data">Our study has several strengths. Multiple uncontrolled factors may contribute to heterogeneity of metabolomic profile. We included 2 sub-populations with relatively large sample sizes to partially address the inherent shortcoming of a metabolomics study. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In addition, the coverage of metabolites in our study is broader than that in early reports. These strengths have enabled us to identify several novel pathophysiological features associated with DKD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">Nevertheless, several weaknesses should be mentioned, as follows: (i) This is a cross-sectional study in its design. Our data can show association but not causality. (ii) Some important clinical variables such as physical activities, diet, and comorbidities were not considered in our current study. Although the inclusion of 2 independent sub-populations may partially address this concern, validation of our findings by other independent studies is warranted. (iii) We measured urinary albumin level only once. It has been known that the day-to-day variation of albuminuria level is high (2) (iv) Due to technical limitations, we are not able to separate the isomeric species including C8-OH/ C6-DC, C14-OH/C12-DC, and C18-OH/C16-DC. An early study showed that the signals of these isomers come mainly from branched-chain dicarboxyl-acylcarnitines (22). XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Although targeted metabolomics provides accurate metabolite identification and quantification, it can cover only a subset of the human metabolome. Non-targeted metabolomics is needed to complement our findings. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Finally, we would highlight that participants included in a validation sub-study had “extreme phenotype” in terms of DKD phenotype. Therefore, data obtained from this sub-population should be interpreted with caution. In addition, clinical characteristics of participants and the loadings of factors are different in discovery and validation sub-populations (Tables 1 and 4, Tables S9 and S10). Hence, direct comparisons of factors derived from these 2 subpopulations are not relevant. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">Therefore, the accelerated amino acid catabolism in DKD is intriguing, and the sensory signals that trigger amino acid flux and oxidation in these patients remain largely unknown. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Accumulation of acetyl-CoA-derived C2 (acetylcarnitine), as observed in our study, points to a mismatch between energy substrate flux and its utilization in DKD. However, due to the observational nature of our study, we are unable to elucidate whether the imbalance is due to accelerated flux or a reduced downstream utilization, or both. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">17</td>
<td class="data"> &#160;</td>
<td class="data"> &#160;</td>
<td class="data"> &#160;</td>
</tr>
<tr>
<td class="r data">18</td>
<td class="data">Our analysis and prior studies derived a similar combination of fatty acids [12-15], but no previous studies to our knowledge evaluated T2D incidence as an outcome. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Strengths of this work include the standardised assay of fatty acid profiles in an EPIC-Inter-Act population with geographic diversity; the large study size (to our knowledge by far the largest among studies of fatty acid biomarkers), allowing various sensitivity analyses; and the generalisability of our findings, strengthened by our findings across 8 European countries and the US NHANES. By focussing on a single combination of fatty acids, we were able to report details of its association with incident T2D and metabolic, genetic, and dietary factors. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">However, this also limited our investigation of other fatty acid patterns, in particular in relation to omega-3 fatty acids. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Other limitations include possible residual confounding by factors unmeasured or measured imprecisely, although we adjusted for many covariates including major risk factors for T2D. Whether or not the combination of fatty acids itself caused the T2D onset remains unestablished. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Possible exposure misclassification due to single fatty acid measurements and possible outcome misclassification were limitations, but likely to be independent of T2D case status and fatty acid profiles, respectively. We found no strong reason to think that these limitations would alter the overall conclusions. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Lastly, the generalisability of our findings might be limited to high-income Western populations, and fatty acid patterns in other populations with diverse genetic backgrounds and dietary patterns are of future interest. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">Associations of gene variants with fatty acids and with incident T2D cannot be confounded by long-term lifestyle characteristics. Therefore, the specific gene variants, the identified combination of fatty acids, and the risk of T2D are likely to be on the same causal pathway, warranting future research to elucidate how insulin resistance specifically alters fatty acid profiles or vice versa. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In contrast, an association with ischaemic heart disease or stroke was not significant [15]. The inconsistency depending on outcome is predictable as DNL could promote insulin resistance, but suppress atherosclerosis [36]. Statins and other lipid-lowering drugs also alter fatty acid profiles [10] and have divergent effects on heart disease and T2D [40]. Thus, a fatty acid pattern can be a future focus of investigations of cardiometabolic diseases and related interventions. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The association of the FA-pattern score with incident T2D was not fully explained by any single fatty acid, but was partly attenuated by adjustment for odd-chain SFAs and VLSFAs. These SFAs are associated with lower risk of cardiometabolic diseases [16,41,42], while their biological roles remains understudied. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX High phospholipid VLSFAs may reflect high activity of PPARα, which leads to VLSFA synthesis and less insulin resistance, apoptotic cell death, and
pancreatic dysfunction [41,43]. Blood odd-chain SFAs may partly reflect dairy consumption [3,44], gut microbiota [45], or endogenous synthesis through α-oxidation [46], and thus any correlates to those factors could explain our findings. Evidence for these mechanisms and relationships with other fatty acids remains scarce and deserves further investigation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The combination of fatty acids warrants further investigation of its determinants and potential application as a marker of metabolic characteristics.</td>
</tr>
<tr>
<td class="r data">19</td>
<td class="data"> &#160;</td>
<td class="data">women aged 64 + sample size of 600 =&gt; adequate for detecting differences in glucose tolerance BUT not for new T2D cases over 5 years =&gt; this is needed to build a robust predictive model based on metabolomics data only</td>
<td class="data">Ultimately, a combination of different markers =&gt; reflect different risk factors + mechanisms behind T2D development =&gt; measure for T2D + indication of what is inducing dysregulation of glucose metabolism =&gt; instructive for clinicians treating T2D. XXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">20</td>
<td class="data">A strength of our study is its prospective design using general population-based cohorts. Study participants were initially free of MI, and thus we analysed only incident events. All samples were handled in a similar, unbiased manner. We controlled for a variety of demographic characteristics, lifestyle factors, medication and clinical variables. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX All data were collected and verified by trained personnel (16,23, 25) to reduce measurement error. We applied stringent QC procedures to our metabolite assays, (18) and observed no sources of systematic error. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Though nested case–cohort and case–control designs are less efficient than assaying the entire cohort, (43) we still observed associations with our approach. Also, associations for the LPC 18:2 and the metabolite score were similar for KORA and AGES-REFINE despite reports of potential bias with stratified case–control designs. (43) XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">A limitation of using backward stepwise selection to reduce the set of predictors is that the pruning is done in an agnostic manner. Thus, the predictors selected may not represent the most meaningful or causal metabolites, but may be markers for unmeasured or unselected metabolites. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We were unable to control for dietary intake, which is associated with incident MI. (44) This may have affected our inability to identify associations with metabolites influenced by diet, for example, tryptophan. (45, 46) Additionally, the non-fasting status of the KORA S2 cohort may have introduced variability that obscured associations in this cohort. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A key point of all biomarker discovery studies is generalisability. We incorporated samples from Germany and Iceland indicating that our associations generalise across European populations.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">We suggest that future studies of MI and metabolic profiles collect detailed dietary information and use fasting samples. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Although we provide substantial evidence for improved baseline discrimination for future incident MI for our novel biomarkers, future studies are needed to formulate and validate an incident MI risk scoring function based on these metabolite biomarkers.</td>
</tr>
<tr>
<td class="r data">21</td>
<td class="data">confounding factors =&gt; dietary FA intake + highlights that MR studies have the power to disentangle causal mechanisms that may be obscured in cross-sectional studies XXXXXXXXXXXX   XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX    Strengths of study =&gt; extensive testing for violations of MR assumptions + replication of main findings using large independent cohorts (different methods for quantification) + use of gold standard measures for IR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX    Pleiotropy =&gt; no evidence, genetic instruments showed associations with cardiometabolic traits that were in expected directions + causal estimates agreed between different analysis methods. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">The study did not evaluate the longitudinal effect on CVD. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Limitations of our study =&gt; moderate power in MR studies + inherent limitations of untargeted metabolomics discovery platform =&gt; metabolite capture (e.g. polar amino acids) + separate sugars + other non-polar molecules. Untargeted metabolomics =&gt; detected several thousand metabolic features =&gt; but limited availability of standard compound spectra in in-house + public libraries =&gt; prevented quantification of the entire spectrum of plasma metabolome =&gt; biased pathway enrichment analysis. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Causal relationships =&gt; consistent across studies BUT vaildation required of physiologic models of IR =&gt; some sources of bias e.g. canalization (unmeasured horizontal pleiotropy) =&gt; cannot be eliminated. Unique contribution of this study =&gt; assess causal effects on the plasma metabolome COULD NOT =&gt; examine reverse causality due to lack of genetic instruments available for majority of metabolites. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">Future studies =&gt; hypothesized but untested relationship with cardiovascular disease requires further investigation. The effect of IR =&gt; elevated tyrosine =&gt; non-significant tendency in all cohorts =&gt; reached nominal significance after =&gt; combn of estimates in meta-analysis =&gt; Future studies =&gt; considerable risk of result being false +ve due to multiple testing =&gt; further investigation in larger MR studies (not been reported before). Associations between worse IR / T2D risk + circulating tyrosine levels =&gt; established in observational + longitudinal studies (42, 43)  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Speculation =&gt; the identified association between tyrosine + increased T2D risk =&gt; due to concomitant IR =&gt; observed trends need to be confirmed through larger samples. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Relative circulating levels =&gt; POA + OA =&gt; unlikely to reflect endogenous biosynthesis. Further experimental investigation =&gt; exact contributions of SCD-1, exogenous source, catabolism + excretion.</td>
</tr>
<tr>
<td class="r data">22</td>
<td class="data"> &#160;</td>
<td class="data"> &#160;</td>
<td class="data">With knockout mice + in vivo-active inhibitors of individual FAHFA hydrolases =&gt; enrich understanding of respective roles that these enzymes and their lipid substrates play in mammalian biology + disease.</td>
</tr>
<tr>
<td class="r data">23</td>
<td class="data">To the best of our knowledge, the current study was the first study showing that acylcarnitines could effectively predict incident diabetes, by an accurate quantification of relevant metabolites (18). XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">However, our study also has some limitations. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX First, only 77% of participants were successfully followed up, and a few baseline characteristics were found different comparing those lost to follow-up with all eligible participants, including more urban residents, and high levels of educational attainment, family income, and plasma triglycerides (13). Nevertheless, the follow-up rate was comparable to other prospective studies conducted in comparable age-groups (44,45). XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Second, the diagnosis of diabetes in the current study was based on either self-report, taking diabetes medications, or a single fasting glucose, which did not constitute a rigorous evaluation for the presence or absence of diabetes. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Third, our participants are limited to middle-aged and elderly Chinese adults, who might have a higher risk of developing diabetes than Caucasians and younger adults. Thus, it is unknown whether the results could be extended to other age, racial, and ethnic groups. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Finally, although our results were internally
cross-validated, it is critical that they are independently replicated in different prospective cohorts. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">These findings need to be replicated in other populations, and underlying biological mechanisms should be elucidated in future studies. XXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">24</td>
<td class="data"> &#160;</td>
<td class="data">The histological analysis of A-SMase performed in the present study is limited by the fact that the method does not allow SMase activity assessment. However, the additional in vitro experiments provide evidence that the analyzed lipids are important for plaque inflammation and the induction of cellular apoptosis. Furthermore, no differential expression of enzymes was observed, which may be a power issue because of the small number of plaques used for RNA sequencing</td>
<td class="data">As the synthesis and degradation of sphingolipids are tightly regulated by a broad spectrum of enzymes, RNA sequencing was performed to investigate whether an increase in plaque levels of sphingolipids and glycosphingolipids could be explained by differential expression of genes coding for enzymes involved in relevant pathways. In the current analysis, no significant differences in the expression of these enzymes were observed. This does not rule out the role of these enzymes in plaque progression, as enzyme activity or localization could also be involved and remain to be evaluated. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  In addition, sphingolipids should be further evaluated as possible biomarkers of plaque vulnerability.</td>
</tr>
<tr>
<td class="r data">25</td>
<td class="data">The present report has several strengths, by extending the previous observations in important directions. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX First, we demonstrate in a prospective study that the previously reported association of lower adiponectin levels with increased risk of T2DM manifests at a more proximal stage, and is evident during transition from normoglycemia to prediabetes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Second, our findings suggest that the putative mechanisms whereby adiponectinemia interacts with glucose homeostasis to confer protection against dysglycemia are operative even in persons who are among the highest risk groups for diabetes, namely, offspring of parents with T2DM. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Third, our findings were obtained from a biracial cohort and were consistent in men and women, indicating that the known gender and ethnic differences in adiponectin expression do not abrogate the interaction between adiponectinemia and glucose homeostasis. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Finally, we have used rigorous methods (including hyperinsulinemic euglycemic clamp and FSIVGTT) to acquire novel biracial data on the associations between adiponectinemia and insulin action, insulin secretion and dyslipidemia in otherwise healthy African-Americans and European Americans. Our data indicate that the association of adiponectin with insulin sensitivity is particularly robust among African-Americans (table 2), which suggests that interventions that increase adiponectin secretion may have enhanced insulin-sensitizing potency in African-Americans. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">The present report has some limitations related to the population studied: our findings were obtained from offspring of parents with T2DM. As these participants represent a selected group at high risk for diabetes, the strong association between baseline adiponectin levels and incident prediabetes may not be exactly applicable to individuals without a family history of diabetes, or the general population. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Also, our analyses focused on baseline adiponectin levels; thus, our assessment did not include the potential effects of changes in adiponectin secretion that may have occurred during the course of the POP-ABC study. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">The mechanisms whereby adiponectin exerts its favorable cardiometabolic effects are not fully understood, but could involve improvement in insulin action, decreased inflammatory tone, interaction with fibroblast growth factor (FGF)-21 and amelioration of lipotoxicity, among others. (34–39) XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">26</td>
<td class="data"> &#160;</td>
<td class="data">The observational assessment of the effects of statins may be confounded, in particular by indication for treatment. However, the comparisons of metabolic changes over 2 time points reduced such confounding. Furthermore, the Mendelian randomization approach to proxy the metabolic effects of HMGCR inhibition is generally free of this limitation (18,40). XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The rs12916-T allele in HMGCR has previously been rigorously associated with lower expression of HMGCR in the liver and lower circulating LDL-C levels (13,19), supporting the validity of this common variant as a genetic instrument. Information on statin type and dosage was generally not available; however, results were coherent across the 4 longitudinal cohorts despite large differences in demographics and follow-up time. The genetic analyses were also consistent across 8 cohorts with a wide age span. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The limited statistical power and the predominantly young study population preclude us from ruling out minor effects of statins on non-lipid biomarkers. Nonetheless, the results set upper limits for the effects of HMGCR inhibition on multiple circulating biomarkers not previously investigated. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data"> &#160;</td>
</tr>
<tr>
<td class="r data">27</td>
<td class="data"> &#160;</td>
<td class="data"> &#160;</td>
<td class="data">Clinical behavior change efforts, health system changes, novel technologies, and robust policy strategies must complement and facilitate these individual food choices, which together will reduce cardiometabolic disease and economic burdens across the population.</td>
</tr>
<tr>
<td class="r data">28</td>
<td class="data"> &#160;</td>
<td class="data">Important LIMITATION to interpreting data in this area =&gt; 1) Generated data is highly correlative 2) Unclear proposed mechn =&gt; PKCe mediated impairment of insulin action =&gt; inhibiting insulin receptor phosphorylation =&gt; insulin resistance (51). Selective insulin resistance =&gt; 1) insulin-mediated suppression of gluconeogenic pathways is impaired in insulin-resistant liver, 2) a pathway that stimulates de novo lipogenesis through the sterol response element binding protein (SREBP1) remains intact (51 - 54). Contradictory findings =&gt; at which step in the bifurcating insulin signalling cascades =&gt; insulin resistance occurs (52 - 54) =&gt; believed to be downstream of insulin receptor. Unclear =&gt; how PKCe-mediated impingement on insulin receptor activity fits in with the widely observed concept and meshes into the broader model of hepatic insulin resistance. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">Address discrepancies + inconsistencies.</td>
</tr>
<tr>
<td class="r data">29</td>
<td class="data">The strengths of this study are that we have measured a large number of biomarkers covering numerous pathophysiological pathways. We have also made use of k-fold cross-validation and machine learning methods that avoid the problem of overfitting when testing large numbers of associations and increase the generalizability of findings to other settings. XXXXXXXXXXXXXXXXXXXXX  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">There are also weaknesses. The sample size is modest and only one cohort has been studied and validation in external cohorts is needed. We used a dichotomous variable for albuminuria because no single method was used for all samples to assess albuminuria status. As a result there is potential for residual confounding because of albuminuria. However, a sensitivity analysis of the subgroup with albumin concentration data measured by a single method showed that the increment in AUROC achieved by adding biomarkers to the clinical covariates was not reduced by the use of a continuous measure of albuminuria rather than the dichotomous variable. Thus, we think it is reasonable to conclude that the biomarkers are not materially affected by residual confounding. Another weakness is that we only have limited data from blinded duplicate samples because of limited volume availability, although in general the repeatability data were good (see Supplementary Methods online). We also note that the effect of errors in measurement act to reduce the power to detect associations rather than introduce false positive associations. Third, we did not have a measure of every biomarker in every sample that required us to impute missing values. However, the degree of missng at random was not high with only 6 biomarkers in the study having ≥30% of values imputed, and a sensitivity analysis examining individual biomarker associations after adjustment for clinical covariates in the non-imputed data showed consistent associations with those seen in the imputed data set. In keeping with our aim to identify biomarkers that might improve clinical trial stratification we have restricted the study to individuals with CKD3 at baseline. It is not possible to conclude that biomarkers that are associated with progression at this stage will also be predictive of progression in individuals with CKD1 or CKD2 and studies are needed to examine biomarkers in such individuals. It should also be noted that panels of biomarkers predicting from earlier stages of renal disease are more likely to include biomarkers that are in the causal pathway, whereas panels predicting from CKD3 may include biomarkers altered secondarily because of declines in glomerular filtration. The study also does not identify</td>
<td class="data">However, further studies of the generalizability of findings are warranted. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Validation in external cohorts is needed. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX It is not possible to conclude that biomarkers that are associated with progression at this stage will also be predictive of progression in individuals with CKD1 or CKD2 and studies are needed to examine biomarkers in such individuals. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Identified novel associations of biomarkers that warrant further investigation for relevance to pathogenesis of kidney disease in type 2 diabetes.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">30</td>
<td class="data"> &#160;</td>
<td class="data">Although our study has several strengths, we also acknowledge some limitations. First, based on our previous studies, we had expected greater IR (Si) and hyperinsulinemia in African Americans with modestly severe obesity and prediabetes than their white American counterparts, but this was not the case. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Second, our observation suggests a possible ethnic and racial threshold effect of obesity (BMI) on glucose homeostasis, insulin sensitivity, and lipid and lipoprotein metabolism, as well as cardiometabolic parameters. This hypothesis deserves further elucidation. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Third, the study was cross-sectional, and hence cause-effect relations among the degree of obesity and cardiometabolic parameters could not be ascertained. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Fourth, the respective putative mechanisms of the paradoxical relationships of IR versus TGs and HDL-C and HDL-C/TG ratio in obese African Americans could not be ascertained in our study. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Fifth, we did not measure the visceral abdominal adiposity that is well established as an important determinant of IR in white Americans, but not in African Americans and other black populations (32–34). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Sixth, there was a sex imbalance with more females than males (8–10:1) in both white Americans and African Americans. However, excluding males from
our analyses did not change the mean values of the anthropometric and metabolic parameters or the relationships of BMI and the Si and cardiometabolic parameters in both ethnic groups. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Finally, the genetic markers for the paradoxical relations of IR and CVD risks in African Americans are not known. Thus, an understanding of the genomic and/or proteomic basis of IR and glucose homeostasis, lipid and lipoprotein synthesis, and catabolism in modestly severely obese African Americans is warranted. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">The mechanism of the putative greater Sg and GEZI values, however, remains to be elucidated in obese and nonobese African Americans with and without prediabetes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The reasons for the IR and lipid / lipoprotein paradox in blacks are unknown. In this regard, ethnic and genetic interactions have been implicated in hepatic lipid and lipoprotein synthesis and clearance as possible mechanisms for the paradoxical differences in lipids / lipoproteins in obese and non-obese African Americans and blacks residing in diverse populations (23). XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We suggest that longitudinal studies of underlying putative mechanisms and molecular targets for glucose homeostasis, lipid/lipoprotein metabolism, and HDL functionality in a large sample of obese African Americans and white Americans are warranted.</td>
</tr>
<tr>
<td class="r data">31</td>
<td class="data">A strength of this study was the use of gold standard methods such as the euglycemic clamp with tracer dilution, coupled with indirect calorimetry. This enabled us to measure both fasting endogenous glucose production and insulin sensitivity, as well as carbohydrate and fat metabolism, both in the basal and hyperinsulinemic state. To our knowledge, this has not been reported in SA subjects with T2D previously. The patients were included by a large variety of approaches, with wide inclusion criteria, the main restriction being the 25-hydroxyvitamin D levels =&lt;50 nM, with the aim of securing broad representativeness. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">The following limitations must be noted: The data presented here are cross-sectional. No efforts towards matching of the two ethnic
groups at baseline were made. The inclusion of SA patients in the study proved challenging, hence the SA group was limited in size, increasing the risk of Type II statistical errors. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Type II error means failing to conclude there was an effect when there actually was. In reality, your study may not have had enough statistical power to detect an effect of a certain size. (FALSE NEGATIVE)) XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Further studies in a larger group of patients, will therefore be necessary to confirm some of the findings that are still uncertain in our study. We selected only subjects with low levels of vitamin D, and our results therefore cannot be generalized to the whole population of subjects with T2D, although low vitamin D levels are common in T2D. Nevertheless, we did not find any correlation between 25-hydroxyvitamin D levels and insulin sensitivity or insulin secretion. This is an exploratory study, and we have judged it appropriate not to show p-values corrected for multiple testing. Bonferroni-Holm corrections were performed, showing that p-values &lt;0.01 remained significant. However, due to the high risk of missing a genuine difference that is clinically significant, we still focus on the non-corrected tests [40]. Hence, there is also a risk of reporting p values &lt;0.05 by chance. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">The inclusion of SA patients in the study proved challenging, hence the SA group was limited in size, increasing the risk of Type II statistical errors.  Further studies in a larger group of patients, will therefore be necessary to confirm some of the findings that are still uncertain in our study. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  Findings of near significant correlations between REE, EE clamp and EGP in the SA group only, might indicate increased post-absorptive glucose metabolism in the SA group, at the expense of lipid metabolism, but these results have to be confirmed in larger studies. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">32</td>
<td class="data">A strength of our study was that desaturase activities were calculated on the basis of fatty acid compositions in four different lipid pools. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX It was, therefore, possible to evaluate consistencies between pools in the calculated desaturase activities and we were able to demonstrate complete consistency for elevated SCD-16 activity in white Europeans compared with African Caribbeans or Asian Indians. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These differences have not been investigated previously, but their strength and consistency in our analysis justifies further, dedicated confirmatory studies. By contrast, reduced D6D activity in Asian Indians and elevated D5D activity in African Caribbeans was restricted to activities calculated from the CE and PL pools. This suggests ethnic variation in desaturase activities in specific tissues, most likely the liver, and justifies further investigations of ethnic variation in tissue-specific desaturase activities. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">Our study has limitations in that it was restricted to a subgroup of a larger cohort [27] and both the African Caribbean and Asian Indian women were slightly but significantly younger than the Europeans. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Previous studies [1,28-30], including the full cohort study from which the present analysis was drawn [27], report that, compared to European women, African Caribbean women have higher BMI, higher or similar systolic and diastolic BP, similar HDL cholesterol, lower triglycerides and decreased insulin sensitivity, whereas Asian Indian women have higher or similar BMI, similar blood pressure, lower or similar HDL cholesterol, higher or similar triglycerides and lower or similar insulin sensitivity. X XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Ethnic differences in these measures in the present study were, therefore, broadly similar to previous findings, although in our smaller subgroup we found no significant difference in triglyceride levels between European and African Caribbean women. The systematic multivariable analysis we adopted was designed to minimize any effects of these differences in risk factors on relationships between desaturase activities and ethnicity. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A further potential limitation was that the study from which the present analysis derives did not include recording of dietary information. There is undoubtedly considerable ethnic variation in dietary habits, but it is important to note that our analysis concerned measures derived from precursor-to-product ratios, which should be relatively uninfluenced by variation in absolute levels of either precursors or products. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">Genetic variation might underlie the lower D6D activity in Asian Indians but definitive studies of ethnic variation in the Fads2 gene that codes for D6D have yet to be carried out. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX D5D is coded by the Fads1 gene and it has been suggested that the higher arachidonic acid levels in African Caribbeans could reflect ethnic differences in Fads1 genotype [19,20]. However, as with the Fads2 gene, ethnic variation in Fads1 genotype has yet to be explored in depth. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We found no evidence for an association between SCD activity and insulin sensitivity but previous studies have reported positive [13] or negative [15] associations between SCD activity and insulin sensitivity so this issue remains unresolved. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">33</td>
<td class="data"> &#160;</td>
<td class="data"> &#160;</td>
<td class="data">We need future studies to define ethnic-specific cut-points for central obesity. Although we did not address obesity as a stand-alone disorder in this statement, there is growing understanding of the neuroendocrine regulation of appetite and energy expenditure that contribute to obesity (435); however, basic science and translational studies are needed to determine whether these mechanisms differ by race / ethnicity.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXSex disparities exist in certain endocrine disorders, with autoimmune thyroid disease and cardiovascular complications of diabetes being more common in women than men. The etiology of these sex differences remains unclear and warrants further basic and clinical research. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Data on the prevalence and incidence of osteoporotic fractures in minority men are lacking, suggesting a need for further investigation given the aging of our population. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A major gap in our current understanding of race / ethnic disparities in endocrine disorders is a failure of most studies to specify Hispanic-American and Asian-American subgroups. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In this statement, we have attempted to specify ethnic subgroups where they were identified in certain studies; however, the majority of studies did not clearly define subgroups. Where these data are available, there are clear ethnic-specific differences within Hispanic and Asian subgroups, particularly related to diabetes and obesity risk. Thus, it is imperative that future studies accurately identify ethnic subgroups. In general, except for diabetes, there are few data on endocrine disorders in Native Americans and Alaska Natives, an important population for future research as well. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX For the endocrine disorders discussed in this statement, there is little evidence that genetic differences are a significant contributor to race / ethnic disparities; however, there is likely significant heterogeneity and admixture among populations, which may mask genetic differences in GWAS studies. As recently reviewed, however, there are emerging techniques to overcome these challenges in performing GWAS studies in minority populations (436). Future genetic studies should incorporate ancestral markers to account for admixture and more specifically address the contribution of race / ethnicity to disease risk and disparities. There is a paucity of data on race / ethnic differences in responses to various treatments for endocrine disorders, and determining whether these differences exist will allow us to implement more patient-specific treatment regimens. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our improved awareness and knowledge of interventions regarding disparities in diabetes needs to be expanded to other endocrine disorders for which race / ethnic disparities exist. Specifically, it is important to study whether social determinants of disease presented in our health disparities framework, specifically the physical and community context, are important contributors to disparities in vitamin D deficiency and poor outcomes after thyroid cancer diagnosis and osteoporotic fractures in minority populations. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In the field of diabetes, multilevel interventions targeting the patient, provider, health care organization, community and health care system, and policy have reduced disparities in diabetes care and improved quality of care. These successes can be used as a roadmap for designing similar interventions to improve quality of care for endocrine disorders where there is currently a gap—specifically reducing mortality and improving outcomes after thyroid cancer treatment and osteoporotic fractures. Understanding the biological, clinical, and non-clinical contributors to disparities in endocrine disorders will allow the design of effective interventions to reduce these disparities and improve public health. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Finally, according to a 2010 American Association of Medical Colleges survey, just under 27% of our current endocrine workforce is represented by minority physicians—16.9% Asian, 5.7% Hispanic, 3.6% NHB, and 0.3% Native American or Alaska Native—despite several endocrine disorders having a higher burden in these populations (438). Increasing the representation of ethnic minorities in both the clinical and research sectors of endocrinology and diabetes will help to raise awareness and prioritize research funding and policy development to reduce endocrine disparities.</td>
</tr>
<tr>
<td class="r data">34</td>
<td class="data"> &#160;</td>
<td class="data"> &#160;</td>
<td class="data">Remains to be determined =&gt; effects are a consequence of being a direct ligand for LRH-1. Remains possible =&gt; DLPC activates alternative signalling cascade or induces biosynthesis of an endogenous LRH-1 ligand. Identified DLPC =&gt; specific agonist ligand for LRH-1 in vitro. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Future research =&gt; address interesting questions =&gt; whether phospholipid transfer proteins (15) facilitate its transport =&gt; large + dynamic intranuclear pool of phosphatidylcholine (16) =&gt; whether DLPC is an endogenous LRH-1 agonist. Ligand responsiveness of LRH-1 is consistent  with the identification of synthetic agonists =&gt; activate both LRH-1 + SF-1 (17)</td>
</tr>
<tr>
<td class="r data">35</td>
<td class="data"> &#160;</td>
<td class="data"> &#160;</td>
<td class="data">Because of the plethora of physiological processes are regulated by SNS, SCFA-GPR41 interactions that regulate SNS could represent a central mechanism to account for the effects of diet, prebiotic + probiotics on body homeostasis + may represent avenues for understanding + potentially manipulating physiology + disease.</td>
</tr>
<tr>
<td class="r data">36</td>
<td class="data"> &#160;</td>
<td class="data"> &#160;</td>
<td class="data"> &#160;</td>
</tr>
<tr>
<td class="r data">37</td>
<td class="data"> &#160;</td>
<td class="data"> &#160;</td>
<td class="data">Although recent studies in ZDF (fa/fa) rats suggested an important role for the ceramide pathway in the late destructive phase of lipid overload in the pancreatic β cells [16], the overall underlying mechanisms leading to lipoapoptosis remained poorly understood. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Taking into account that mir-375 also regulates insulin secretion, mir-375 could emerge as a potential therapeutic target for prevention and intervention of β-cell dysfunction and β-mass loss in type 2 diabetes.</td>
</tr>
<tr>
<td class="r data">38</td>
<td class="data"> &#160;</td>
<td class="data"> &#160;</td>
<td class="data">Future studies will address whether the AcylCN profile can serve as a biomarker to assess the response of obese and T2DM participants to interventions. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">39</td>
<td class="data"> &#160;</td>
<td class="data">Other lifestyle factors =&gt; e.g. intensity + regularity of exercise + total daily energy intake =&gt; might be much more important =&gt; causing + maintaining obesity XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In Our opinion =&gt; most probable explanation for the results obtained in our study =&gt; principally different  + contradiction to those obtained through previous studies. Methodological differences in DNA extraction protocols + primer design =&gt; could have caused additional variation. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Premature to suggest a certain type of gut microbiome to be a biomarker for obesity in humans XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Difficult to draw definite conclusions =&gt; importance of various bacterial groups =&gt; obesity =&gt; because not all influencing parameters =&gt; e.g. diet, genetic background, habitation + overall fitness =&gt; taken into account. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">Find a way to control for =&gt; diet, genetic background, habitation + overall fitness</td>
</tr>
<tr>
<td class="r data">40</td>
<td class="data">1st study reporting the effect of lipid mediators on adipose tissue function + liver steatosis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">Mechns of insulin resistance =&gt; hepatic steatosis =&gt; unclear. XXXXXXXXXXXXXXXXXXXXXX  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  Altered insulin sensitivity =&gt; increases hepatic de novo lipogenesis + induces lipolysis of adipocyte TGs + flux of free fatty acids to liver. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXF4 / 80 monoclonal antibody used in these experiments cannot distinguish between recruited + resident macrophages =&gt; results cannot establish whether resolvin E1 decreases macrophage infiltration or this lipid mediator affects Kuffer cells, the liver resident macrophages. XXXXXXXXXXXXXXXXX</td>
<td class="data">Cannot distinguish between recruited and resident macrophages. Does Resolvin E1 decrease macrophage infiltration, or does this lipid mediator affect Kuffer cells (liver resident macrophages)? XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">41</td>
<td class="data"> &#160;</td>
<td class="data">The major limitation of this study is the number of subjects investigated. The number was limited by the complexities of the metabolic and imaging studies. For this reason, addition studies are needed to confirm our conclusions. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX One other limitation of the study is that South Asians had higher percentage of subjects with family history of diabetes which could be a confounding factor. However, the ethnic differences in insulin resistance also translate in to higher prevalence of type 2 diabetes in South Asians and random selection of healthy young volunteers is bound to result in this difference in family history of diabetes between Caucasians and South Asians. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX One other limitation of this study is lack of dietary information in the two groups. However, reported frequency of exercise was similar in both the groups. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Although we have shown that abnormalities in adipose tissue amounts, distribution, and function can account for a significant portion of the predisposition of South Asians to insulin resistance, we cannot rule out the possibility that genetic factors of a more generalized nature also contribute to insulin resistance. For example we have shown that South Asians have a relative increase in a polymorphism of ENPP1/PC-1 that has been reported to be associated with increased insulin resistance and predisposition to type 2 diabetes [5,6]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">The major limitation of this study is the number of subjects investigated. The number was limited by the complexities of the metabolic and imaging studies. For this reason, addition studies are needed to confirm our conclusions. XXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">42</td>
<td class="data"> &#160;</td>
<td class="data"> &#160;</td>
<td class="data">Whether this increase in plasma IL-6 concentration is playing a causative role for the increased prevalence of insulin resistance in the Asian-Indian men or is secondary to the hepatic steatosis and insulin resistance remains to be determined. XXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">43</td>
<td class="data"> &#160;</td>
<td class="data"> &#160;</td>
<td class="data">Although we believe that the highly significant findings (P=0.001) are robust, given the number of hypotheses tested and our use of stepwise methods, replication in other data sets is warranted. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The present study provides supportive data that might explain this finding; whether these demonstrated pro-atherogenic lipoprotein abnormalities in prediabetic individuals are related to increased insulin resistance or rather impairment in insulin secretion is the topic of further ongoing analyses. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">44</td>
<td class="data"> &#160;</td>
<td class="data"> &#160;</td>
<td class="data">At present (future research) =&gt; not yet examined DHHC7 KO mice in terms of glucose + energy metabolism. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX At present (future research) =&gt; the mechanism by which insulin promotes DHHC7 autopalmitoylation remains to be determined. DHHC7 exists as a multi-subunit complex =&gt; includes regulatory + catalytic subunits =&gt; DHHC7 as the catalytic subunit. When overexpressed =&gt; other subunits might then be titrated out. As a result =&gt; the ectopically expressed DHHC7 becomes super-active =&gt; which will comprimise its enzyme specificity. This probably explains =&gt; why DHHC2, DHHC3 + DHHC7 =&gt; found to palmitoylate many proteins in-vitro screening (7). Recent studies =&gt; DHHC3 is subject to tyrosine phosphorylation at multiple tyrosine residues =&gt; influences DHHC3 autopalmitoylation (45). It is possible =&gt; insulin promotes DHHC7 tyrosine phosphorylation at specific tyrosine =&gt; regulates DHHC7 PAT activity. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 1) How DHHC7 autopalmitoylation is regulated by insulin 2) How inactivation of DHHC7 in mice affects glucose + energy metabolism</td>
</tr>
<tr>
<td class="r data">45</td>
<td class="data"> &#160;</td>
<td class="data"> &#160;</td>
<td class="data">It may be that dual agonism with PPAR-a/Y agonists will provide additional benefits above and beyond those achieved with sole activation of either PPAR-a or PPAR-Y.</td>
</tr>
<tr>
<td class="r data">46</td>
<td class="data"> &#160;</td>
<td class="data"> &#160;</td>
<td class="data">However, the beneficial effects of metformin on prevention of type 2 diabetes still await confirmation from undergoing clinical trials specifically designed to answer this important question. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXThe role of TZDs in prevention of type 2 diabetes still awaits evaluation.</td>
</tr>
</tbody>
</table>
</div>
</div>
</body>
</html>
